

Building a Health System that can Ensure Healthy Longevity in an Era of 100 Year Lifespans

Three Concepts to Guide Policy

3 Concepts

Concept

It is important to seek out ways to make the healthcare system more effective and efficient.


L

Concept 2

Money is not "spent" on the healthcare system, it is invested.

Implement these concepts by promoting:

- Measures to increase spending efficiency
- Regulatory Science measures to reduce the costs of R&D and improve market access
- **Y** The further development of push and pull incentives for innovation
- Measures to strengthen healthcare data infrastructure to better inform policy debates
- Innovative financing mechanisms to help fund new treatments and health interventions
- Policymaking that reflects patient values



Outline of **Policy Options**

Health and Global Policy Institute (HGPI) formed an expert taskforce in FY2019 to debate the future of the health system. The chart below outlines the discussion that took place in that taskforce.

Promoting Efficiency & Optimization

Investments for the Future

Increasing **Healthy Life Expectancy**

Spending Efficiency

Expand the HTA* system to cover the entirety of healthcare system spending, create measures to guide investments

Foster experts in health economics and outcomes research who can improve system sustainability over the long term Increase spending efficiency to create a financially stable healthcare system that can support public health

Regulatory Science (Discussion led by Mitsuo Umezu)

Streamline R&D by promoting mutual recognition and rapid approvals while also considering safety and efficiency Foster experts in regulatory science that can evaluate pharmaceuticals and medical devices from multiple perspectives

Increase market access for innovative medical technology, and ensure the provision of advanced healthcare

Incentives

Advance healthcare reform through the use of disincentives

Promote highly effective healthcare through the use of push and pull incentives

Promote reforms that can increase healthy life expectancy through the use of a balanced mix of incentives

Healthcare Data Infrastructure

(Discussion led by Eiko Shimizu)

Fully harness existing databases by better maintaining master data dictionaries and analysis infrastructure

Data infrastructure, as well as individual data records (including PHR**) must be made more robust for use in policymaking

Use healthcare data to develop policies and evidence that can contribute to increases in healthy life expectancy

Financing/ **Payments**

Adjust medical prices using a prioritization scheme that respects patient values while also considering competitiveness in the healthcare industry

Improve system efficiency while meeting

Introduce a budget mechanism that would force adjustments to some portion of system funding in line with GDP growth

Construct a sustainable health system by securing stable financial resources and adjusting medical fees

Value-based Policy

the diverse demands of users by introducing pricing evaluations that (Discussion led by Ataru Igarashi) reflect patient values

Consider the impact of health technology on patient lifestyles when evaluating prices to promote technology that protects productivity

Ensure that the health system fulfils its role as the foundation for a healthy aging society by evaluating medical technology based on a diverse set of values

Note: Please see the taskforce's report for a detailed description of each policy option

- *Health Technology Assessment
- **Personal Health Records

Taskforce members (alphabetical order by last name)

Mamoru Ichikawa (Principal Program Director, Japan Broadcasting Corporation (NHK))

Ataru Igarashi (Associate Professor, Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine)

Satoshi Imamura (Vice-President, Japan Medical Association)

Isao Kamae (Project Professor, Graduate School of Public Policy, The University of Tokyo)

Toshio Nagase (Government Affairs Japan, Gilead Science K.K.)

Hiroshi Nakamura (Professor, Graduate School of Business Administration, Keio University)

Kazumasa Oguro (Professor, Faculty of Economics, Hosei University)

Naokazu Saito (Director, Policy Intelligence Department, Janssen Pharmaceutical K.K.)

Naomi Sakurai (President, Cancer Solutions Co., Ltd.)

Eiko Shimizu (Project Associate Professor, ITHC, Graduate School of Pharmaceutical Sciences, The University of Tokyo)

Mitsuo Umezu (Director, Institute for Medical Regulatory Science, Waseda University)

Hirokazu Yoshii (Special Advisor to the President, Health Insurance Claims Review & Reimbursement Services)

This project was carried out using the Chatham House Rule, which prohibits the attribution of any specific remark to any specific speaker. This document and the taskforce's report were compiled by HGPI and contributing authors, and the opinions expressed within should not be construed to represent the opinion of any one project participant.



Health and Global Policy Institute

Grand Cube 3F, Otemachi Financial City, Global Business Hub Tokyo 1-9-2, Otemachi, Chiyoda-ku, Tokyo, 100-0004 Japan Tel: 03-4243-7156 Fax: 03-4243-7378 E-mail: info@hgpi.org